SG/CALL/ABBVIE/190/0.1/21.03.25 Stock

DE000SW7LC80

Market Closed - Boerse Frankfurt Warrants 02:18:06 2024-06-14 pm EDT
0.54 ^EUR	+12.50%

Current month	+45.45%
1 month	+23.08%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ABBVIE INC.

Latest news about ABBVIE INC.

AbbVie inks immune disorder drug licensing deal with China's FutureGen	Jun. 13	RE
AbbVie, FutureGen in License Pact for Inflammatory Bowel Disease Drug	Jun. 13	DJ
AbbVie, FutureGen to Develop Potential Inflammatory Bowel Disease Treatment	Jun. 13	MT
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease	Jun. 13	PR

More news

Quotes 5-day view

Date	Price	Change
24-06-14	0.54	+12.50%
24-06-13	0.48	+2.13%
24-06-12	0.47	-11.32%
24-06-11	0.53	-13.11%
24-06-10	0.61	+8.93%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 02:18 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ABBVIE INC.
Issuer	Société Générale
WKN	SW7LC8
ISIN	DE000SW7LC80
Date issued	2024-03-12
Strike	190 $
Maturity	2025-03-21 (280 Days)
Parity	10 : 1
Emission price	1.23 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.36 €
Lowest since issue	0.23 €
Spread	0.03 €
Spread %	5.17%

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

More about the company